Use of gabaa modulators for treatment of respiratory conditions
AssigneeSage Therapeutics, Inc.
InventorStephen Jay Kanes
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treating a symptom of a respiratory condition, in a subject, comprising administering to the subject an effective amount of a GABAA PAM.
Claims75
A method of treating a respiratory disease or condition, or a symptom of a respiratory disease or condition in a subject in a subject, comprising administering to said subject a therapeutically effective amount of a GABAA PAM, or a pharmaceutically acceptable salt or crystalline form thereof, wherein the GABAA PAM is selected from the group consisting of allopregnanolone, gaboxadol, ganaxolone, TP-003, α5IA, bamaluzole, saripidem, necopidem, Compound 1, and a compound selected from the compounds listed in Table 1.
The method of claim 58, further comprising the steps of:
- a. decreasing the administration rate to about 120 μg/kg/h for one hour;
- b. further decreasing the administration rate to about 90 μg/kg/h for one hour;
- c. further decreasing the administration rate to about 60 μg/kg/h for one hour;
- and
- d. further decreasing the administration rate to about 30 μg/kg/h for one hour.
Dependencies are inferred from the claim text.